KKR & Co. closed its $5.89 billion acquisition of Integer Holdings, a medical device manufacturer, in August—a month when global private equity dealmaking otherwise fell off a cliff. The Integer transaction alone accounted for nearly half of healthcare's total buyout activity for the month and became the sole billion-dollar-plus PE deal in a period marked by financing paralysis and sponsor retreat.
Global private equity deal volume dropped sharply in August, with total announced transactions declining by double digits compared to July and year-ago figures. Healthcare emerged as the only sector posting material activity, driven almost entirely by the Integer acquisition. The deal valued Integer at roughly 11.2x trailing EBITDA, a premium to recent medical device comparables but consistent with KKR's thesis that outsourced manufacturing for implantables and neuromodulation devices carries structural margin expansion as regulatory barriers rise. Integer generates approximately $1.4 billion in annual revenue across cardiac rhythm management, neuromodulation, and portable medical product lines, with 72% of sales tied to recurring device production contracts.
The transaction signals two market realities allocators should note. First, healthcare M&A remains the only sector where sponsors can secure committed financing at scale. Integer's debt package closed at 5.8x leverage with a blended cost near 8.1%, materially tighter than consumer or industrial deals of similar size have achieved since June. Second, KKR's willingness to deploy nearly $6 billion into a single platform—its largest healthcare services buyout since Envision in 2018—suggests the firm expects a prolonged window where smaller funds cannot compete for assets requiring $3 billion-plus equity checks. This is consolidation by capital access, not operating thesis.
The Integer deal also marks KKR's third major medical device investment in eighteen months, following minority stakes in surgical robotics and orthopedic imaging platforms. The firm now controls or holds meaningful positions in companies generating a combined $4.7 billion in annual device-related revenue, creating optionality for bolt-on acquisitions and shared purchasing leverage across implantable supply chains. Worth noting: Integer's manufacturing facilities in Mexico and Switzerland provide geographic hedging as tariff risk resurfaces in election-year trade rhetoric.
Operators and allocators should watch three follow-on events. First, whether KKR moves to merge Integer's neuromodulation manufacturing capacity with its existing pain management portfolio companies—a integration that would create the largest outsourced neurostim production platform globally. Second, whether the debt markets remain open for $5 billion-plus buyout financings into September, as Integer's successful syndication may embolden other mega-cap sponsors. Third, whether healthcare deal volume sustains in Q4 or reverts to sector-average performance once Integer's outlier contribution rolls off the monthly figures. Early pipeline data suggests two additional $2 billion-plus healthcare services deals in advanced diligence, but neither has secured committed financing.
The broader August dealmaking drought means KKR's Integer acquisition will likely remain the largest global PE transaction for the full quarter. That is not a commentary on Integer's merits. It is a statement about how quickly capital markets can freeze everywhere except the one sector where cash flows remain contractually predictable and regulatory moats deepen each year.